Elbasvir/grazoprevir treatment in an HCV-infected peritoneal dialysis patient

Jin Chena, b, Yi Li a, b, Guisen Lia, b and Lei Pu a, b

a School of Medicine, University of Electronic Science and Technology of China; b Department of Nephrology, Sichuan Provincial People’s Hospital

ABSTRACT
Hepatitis C virus (HCV) infection is known to affect long-term patient survivals. Elbasvir/grazoprevir (EBR/GZR) has shown a high cure rate in hemodialysis patients with HCV infection. However, the combination is rarely used in peritoneal dialysis patients. Herein, we report a case of successful treatment with EBR (100 mg) and GZR (50 mg) once daily for 12 weeks. Hepatitis C virus RNA was undetectable 4 weeks after the treatment. She achieved a sustained virological response at 12 weeks after the end of treatment. Only fatigue was reported as side effect during the treatment. Thus, elbasvir/grazoprevir was effective and safe in this PD patient with HCV genotype 1b infection.

Case report
A 54-year-old Chinese woman with chronic HCV infection and CKD G5D on PD was referred for anti-HCV therapy. Recent abdominal computed tomography scan and transient liver elastography (Fibroscan) indicated normal findings; there was no evidence of liver cirrhosis or a tumor. Laboratory tests showed an HCV load of 1.44E+06 IU/mL and positivity for HCV genotype 1b. The patient tested negative for human immunodeficiency and hepatitis B viruses. The hemoglobin (Hb) level was 93.0 g/L, the serum aspartate transaminase (AST) was 28 U/L, the alanine transaminase (ALT) concentration was 15 U/L and the urea clearance index was 1.93/week.

Elbasvir/grazoprevir (EBR/GZR) is a fixed-dose combination treatment for HCV genotype 1 or 4 infection. The efficacy and safety of EBR/GZR in CKD patients, including those on HD, has been reported in studies [7–10]. However, to our knowledge, there are no reports on EBR/GZR use in HCV-infected PD patients. Herein, we report a case of successful treatment of HCV genotype 1b infection in a PD patient by using EBR/GZR.
dysfunction. The patient lost residual renal function during the dialysis. The patient’s medications included erythropoietin, iron, calcium acetate and atorvastatin. The PD prescription was a total volume of 8 L, 6 L of 1.5% PD fluid, and 2 L of 2.5% PD fluid.

HCV treatment was initiated with EBR 50 mg and GZR 100 mg once daily for 12 weeks. Atorvastatin was stopped for drug–drug interactions with EBR/GZR before treatment. Hepatitis C virus RNA, Hb, AST, ALT, albumin (Alb), and total bilirubin (TBIL) were monitored every 4 weeks. A sustained virological response was defined as an HCV RNA level of <15 IU/mL at 12 weeks after the end of treatment.

The treatment was not discontinued due to any adverse event. The patient reported fatigue after starting treatment but it was tolerable. All symptoms resolved after the 12-week treatment completed. The levels of AST, ALT, Alb, TBIL, and Hb were stable (Figure 1). Hepatitis C virus RNA was undetectable in plasma after 4 weeks of treatment, sustained virological response were achieved.

Discussion

Treatment of HCV-infected dialysis patients can eliminate the infection source, reducing the chances of transmission. There is a significant survival benefit of HCV treatment both in the general population and HD patients [11,12]. The decision to treat HCV in dialysis patients should be based on health benefits, the risks and costs of therapy [13]. Although the possibility of HCV transmission is much lower in PD patients than in HD patients, antiviral therapy should be considered for improving survival and life quality in PD patients. Many of the approved DAAs therapies are not ideal regimens for dialysis patients because they contain drugs that are eliminated by the kidney.

There are very few reports on DAA regimens in PD patients. Aggarwal et al. treated HCV-infected dialysis patients with 15 sofosbuvir/velpatasvir courses, one PD patient enrolled. Treatment was generally safe and well tolerated. Patient achieved SVR12 after the therapy [14]. Borgia SM et al. used same regimen for dialysis patients, five PD patients included, minor adverse effects were observed in their patients, resulting in a cure rate of 95% [15]. The safety and efficacy of 12-week ombitasvir/paritaprevir/ritonavir treatment in PD patients were evaluated by Shuster et al. and Stark et al. Intensive pharmacokinetic data showed the individual concentration–time profiles for the drugs overlapped among patients, with considerable inter-patient variability. PD had minimal effects on drugs exposure (area under the curve, AUCs). All of their three PD patients completed treatment and achieved SVR12 [16,17]. London et al. described Ombitasvir/paritaprevir/ritonavir and dasabuvir or Ombitasvir/paritaprevir/ritonavir with or without ribavirin (RBV) regimens in CKD patients, included twelve PD patients, no statistically significant differences were found across renal stages. Although anemia, asthenia and pruritus were the most common adverse events during treatment, regimens were also well tolerated in these patients. High SVR12 rate obtained (92.6%) is particularly noteworthy [18]. The above-mentioned reports indicated high cure rates and favorable safety profiles for the drugs in PD patients.

EBR, a nonstructural protein 5A inhibitor, and GZR, an HCV nonstructural 3/4A protease inhibitor, can effectively inhibit replication of HCV genotype 1 and 4.
The apparent terminal elimination t1/2 of both drugs were similar between health group and severe renal impairment group. Both drugs mostly eliminated through feces, with <1% being excreted in urine. Dialysis did not remove any EBR (0%) and removed < 0.5% of GZR from plasma because of high protein binding [19]. Their removal by PD is also unlikely since they are highly bound to plasma protein, as reported in the prescribing information (Merck & Co., Inc.). Although pharmacokinetic analyses show that AUCs are higher in individuals with HD (up to 46% higher compared with individuals with normal kidney function), these changes in exposure to the drugs are not considered clinically relevant [20]. No dosage adjustment of EBR/GZR is required in people with any degree of renal impairment, including those receiving dialysis [19]. The most common adverse events (≥10% frequency) were fatigue, headache, nausea, insomnia, decreased hemoglobin. Others included loss of appetite, asthenia, abdominal pain and dyspepsia [7,21].

Toxicity and intolerable adverse effects were primary concerns of DAAs in CKD patients, especially whom were undergoing dialysis. Since there is no experience about EBR/GZR in PD patients, we followed up the patient closely in order to ensure the safety of treatment. EBR/GZR are substrates of CYP3A, Cytochrome P450 family members. Co-administration with strong CYP3A inducers (such as nifedipine, atorvastatin, simvastatin, amiodarone, commonly used in dialysis patients), it may decreased plasma concentrations and potentially reduced antiviral activity of both agents. We checked combined medication carefully to eliminate the risks of drug–drug interactions during the therapy. The patient tolerated EBR/GZR and only reported treatment-related fatigue (minimal adverse effect). Her Hb level did not decrease, while it was a very common side effect in the C-SURFER study [7]. Her other laboratory parameters including ALT, AST, and TBIL were also stable.

There are limitations of our findings. We did not assess individual drug concentration–time profiles or the EBR/GZR concentrations in the exchanged PD fluid. Moreover, further research on EBR/GZR pharmacokinetics in PD patients is required. In conclusion, EBR/GZR treatment was successful in our PD patient with HCV genotype 1b infection. This is the first report on the safety and efficacy of EBR/GZR therapy in a PD patient.

Compliance with ethical standards
The results presented in this paper have not been published previously in whole or part, except in abstract format. All authors declare no conflict of interest. This study was a case report involving human participant. Informed consent was obtained from participant included in the study.

Disclosure statement
No potential conflict of interest was reported by the author(s).

Funding
Department of Science and Technology of Sichuan Province [Grant no. 2017YSKY0001].

ORCID
Guisen Li http://orcid.org/0000-0003-1970-9979

References
[1] Kidney Disease: Improving Global Outcomes Hepatitis CWG Kdigo 2018 clinical practice guideline for the prevention, diagnosis, evaluation, and treatment of hepatitis c in chronic kidney disease. Kidney Int Suppl. 2011;8:91–165.
[2] Barsoum RS, William EA, Khalil SS. Hepatitis c and kidney disease: A narrative review. J Adv Res. 2017;8(2):113–130.
[3] Goodkin DA, Bieber B, Jadoul M, et al. Mortality, hospitalization, and quality of life among patients with hepatitis c infection on hemodialysis. CJASN. 2017; 12(2):287–297.
[4] Li P-T, Chow KM, Van de Luitjgaarden MWM, et al. Changes in the worldwide epidemiology of peritoneal dialysis. Nat Rev Nephrol. 2017;13(2):90–103.
[5] Vidales-Braz B, da Silva N, Lobato R, et al. Detection of hepatitis c virus in patients with terminal renal disease undergoing dialysis in southern brazil: Prevalence, risk factors, genotypes, and viral load dynamics in hemodialysis patients. Virol J. 2015;12(1):8.
[6] Zineb Lioussfi ZE, Radoui A, Rhou H, et al. Viral hepatitis c and b among dialysis patients at the rabat university hospital- prevalence and risk factors. Saudi J Kidney Dis Transpl. 2014;25(3):672–679.
[7] Roth D, Nelson DR, Bruchfeld A, et al. Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis c virus genotype 1 infection and stage 4–5 chronic kidney disease (the c-surfer study): a combination phase 3 study. Lancet. 2015; 386(10003):1537–1545.
[8] Ogawa E, Furusyo N, Azuma K, et al. Elbasvir plus grazoprevir for patients with chronic hepatitis c genotype 1: a multicenter, real-world cohort study focusing on chronic kidney disease. Antiviral Res. 2018;159: 143–152.
[9] Reddy KR, Roth D, Bruchfeld A, et al. Elbasvir/grazoprevir does not worsen renal function in patients with hepatitis c virus infection and pre-existing renal disease. Hepatol Res. 2017;47(12):1340–1345.
[10] Choi DT, Puenpatom A, Yu X, et al. Effectiveness of elbasvir/grazoprevir in patients with hepatitis c virus
genotype 1 infection and chronic kidney disease in the United States veterans population. Antiviral Res. 2020;174:104698.

[11] Simmons B, Saleem J, Heath K, et al. Long-term treatment outcomes of patients infected with hepatitis C virus: A systematic review and meta-analysis of the survival benefit of achieving a sustained virological response. Clin Infect Dis. 2015;61(5):730–740.

[12] Söderholm J, Millbourn C, Büsch K, et al. Higher risk of renal disease in chronic hepatitis C patients: Antiviral therapy survival benefit in patients on hemodialysis. J Hepatol. 2018;68(5):904–911.

[13] Fabrizi F, Aghemo A, Messa P. Hepatitis C treatment in patients with kidney disease. Kidney Int. 2013;84(5):874–879.

[14] Aggarwal A, Yoo ER, Perumpail RB, et al. Sofosbuvir use in the setting of end-stage renal disease: A single center experience. J Clin Transl Hepatol. 2017;5(06):23–26.

[15] Borgia SM, Dearden J, Yoshida EM, et al. Sofosbuvir/velpatasvir for 12 weeks in hepatitis C virus-infected patients with end-stage renal disease undergoing dialysis. J Hepatol. 2019;71(4):660–665.

[16] Shuster DL, Menon RM, Ding B, et al. Effects of chronic kidney disease stage 4, end-stage renal disease, or dialysis on the plasma concentrations of ombitasvir, paritaprevir, ritonavir, and dasabuvir in patients with chronic HCV infection: Pharmacokinetic analysis of the phase 3 ruby-i and ruby-ii trials. Eur J Clin Pharmacol. 2019;75(2):207–216.

[17] Stark JE, Cole J. Successful treatment of chronic hepatitis C virus infection in a patient receiving daily peritoneal dialysis. Am J Health-System Pharm. 2017;74(19):1541–1544.

[18] Londoño M-C, Riveiro-Barciela M, Ahumada A, et al. Effectiveness, safety/tolerability of obv/ptv/r±dsv in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice – vie-kind study. PLoS One. 2019;14(9):e0221567.

[19] Caro L, Wenning L, Feng HP, et al. Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment. Eur J Clin Pharmacol. 2019;75(5):665–675.

[20] Gamal N, Andreone P. Grazoprevir/elbasvir fixed-dose combination for hepatitis C. Drugs Today. 2016;52(7):377.

[21] Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir–elbasvir combination therapy for treatment-naïve cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection. Ann Intern Med. 2015;163(1):1.